Lista de obras -

A multilocus technique for risk evaluation of patients with neuroblastoma

artículo científico publicado en 2011

A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma

scholarly article by Fiona Herd et al published April 2019 in European Journal of Cancer

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations

scientific article published on 19 September 2019

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms

artículo científico publicado en 2020

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Euro

artículo científico publicado en 2017

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

artículo científico publicado en 2020

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

artículo científico publicado en 2014

Carboplatin therapeutic monitoring in preterm and full-term neonates.

artículo científico publicado en 2015

Cell cycle regulation targets of MYCN identified by gene expression microarrays

artículo científico publicado en 2007

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

artículo científico publicado en 2010

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours

artículo científico publicado en 2018

DNA damage checkpoint kinases in cancer

artículo científico publicado en 2020

Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers

scientific article published on 25 November 2019

Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.

artículo científico publicado en 2003

Differentiation of Human Embryonic Stem Cells to Sympathetic Neurons: A Potential Model for Understanding Neuroblastoma Pathogenesis

artículo científico publicado en 2018

Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line

artículo científico publicado en 2001

Factors associated with recurrence and survival length following relapse in patients with neuroblastoma ⬇️

artículo científico publicado en 2016

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

artículo científico publicado en 2010

High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays

artículo científico publicado en 2007

Histological profile of tumours from MYCN transgenic mice

artículo científico publicado en 2008

Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.

artículo científico publicado en 2007

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse

artículo científico publicado en 2016

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse

artículo científico publicado en 2006

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

artículo científico publicado en 2014

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

artículo científico publicado en 2009

Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior

artículo científico publicado en 2004

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance

artículo científico publicado en 2014

MYCN amplification remains prognostically strong 20 years after its “clinical debut”

artículo científico publicado en 2004

MYCN oncoprotein targets and their therapeutic potential

artículo científico publicado en 2010

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

artículo científico

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma

artículo científico publicado en 2015

Neonatal neuroblastoma.

artículo científico publicado en 2012

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

artículo científico publicado en 2011

Percentage Tumor Necrosis Following Chemotherapy in Neuroblastoma Correlates withMYCNStatus but not Survival ⬇️

artículo científico publicado el 8 de enero de 2011

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

artículo científico publicado en 2015

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

scientific article published on 09 January 2019

SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma

artículo científico publicado en 2015

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

artículo científico publicado en 2011

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma

artículo científico publicado en 2014

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

scientific article published on 03 April 2020

Temporal clustering of neuroblastic tumours in children and young adults from Northern England

artículo científico publicado en 2015

Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada

artículo científico publicado en 2022

The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

artículo científico publicado en 2012

The p53 pathway and its inactivation in neuroblastoma.

artículo científico publicado en 2003

The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage

artículo científico publicado en 2006

The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression

artículo científico publicado en 2019

Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients

artículo científico publicado en 2021

p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells

artículo científico publicado en 2001

p53 is a direct transcriptional target of MYCN in neuroblastoma

artículo científico

p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma

artículo científico publicado en 2007

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance ⬇️

artículo científico publicado el 28 de noviembre de 2012

Lista de obras de

A multilocus technique for risk evaluation of patients with neuroblastoma

A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Euro

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

Carboplatin therapeutic monitoring in preterm and full-term neonates.

Cell cycle regulation targets of MYCN identified by gene expression microarrays

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours

DNA damage checkpoint kinases in cancer

Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers

Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.

Differentiation of Human Embryonic Stem Cells to Sympathetic Neurons: A Potential Model for Understanding Neuroblastoma Pathogenesis

Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line

Factors associated with recurrence and survival length following relapse in patients with neuroblastoma ⬇️

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays

Histological profile of tumours from MYCN transgenic mice

Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance

MYCN amplification remains prognostically strong 20 years after its “clinical debut”

MYCN oncoprotein targets and their therapeutic potential

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma

Neonatal neuroblastoma.

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

Percentage Tumor Necrosis Following Chemotherapy in Neuroblastoma Correlates withMYCNStatus but not Survival ⬇️

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

Temporal clustering of neuroblastic tumours in children and young adults from Northern England

Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada

The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

The p53 pathway and its inactivation in neuroblastoma.

The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage

The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression

Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients

p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells

p53 is a direct transcriptional target of MYCN in neuroblastoma

p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance ⬇️